Thinking about drug costs and basal insulin in type 2 diabetes

Two articles in the May ACP Internist focused on patients with type 2 diabetes—a cover story explained why and how internists should consider patients' drug costs and the latest Pearls from I.M. Peers talked about basal insulin.

More up-front discussion with patients about the costs of newer diabetes drugs, including sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, can improve adherence and save time later. Internists with experience in this area offered their advice on how to raise the issue of drug costs with patients and help them find solutions in a cover story from the May ACP Internist.

In the latest Pearls from I.M. Peers, Irl B. Hirsch, MD, MACP, explained how to start and titrate basal insulin in a patient with type 2 diabetes. Pearls from I.M. Peers focuses on a particular internist's best clinical pearl or solution to a problem, with associated video online, allowing ACP members a chance to offer clinical wisdom in their own words.